HIK vs. HCM, INDV, CTEC, GNS, SN, BMK, APH, BXP, AGY, and ANCR
Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), ConvaTec Group (CTEC), Genus (GNS), Smith & Nephew (SN), Benchmark (BMK), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), and Animalcare Group (ANCR). These companies are all part of the "medical" sector.
Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.
HUTCHMED has a net margin of 12.03% compared to Hikma Pharmaceuticals' net margin of 6.61%. HUTCHMED's return on equity of 14.65% beat Hikma Pharmaceuticals' return on equity.
Hikma Pharmaceuticals received 602 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.56% of users gave Hikma Pharmaceuticals an outperform vote.
37.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.3% of HUTCHMED shares are owned by institutional investors. 30.6% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 42.9% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Hikma Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
Hikma Pharmaceuticals presently has a consensus price target of GBX 2,050, indicating a potential upside of 6.94%. Given Hikma Pharmaceuticals' higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.
In the previous week, HUTCHMED had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 1 mentions for HUTCHMED and 0 mentions for Hikma Pharmaceuticals. Hikma Pharmaceuticals' average media sentiment score of 0.91 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.
Summary
Hikma Pharmaceuticals beats HUTCHMED on 9 of the 17 factors compared between the two stocks.
Get Hikma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hikma Pharmaceuticals Competitors List
Related Companies and Tools
